Success Metrics

Clinical Success Rate
80.0%

Based on 16 completed trials

Completion Rate
80%(16/20)
Active Trials
0(0%)
Results Posted
125%(20 trials)
Terminated
4(20%)

Phase Distribution

Ph phase_1
16
80%
Ph phase_3
4
20%

Phase Distribution

16

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
16(80.0%)
Phase 3Large-scale testing
4(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

16 of 20 finished

Non-Completion Rate

20.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

20

all time

Status Distribution
Completed(16)
Terminated(4)

Detailed Status

Completed16
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
20
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 116 (80.0%)
Phase 34 (20.0%)

Trials by Status

completed1680%
terminated420%

Recent Activity

0 active trials
Showing 5 of 20
terminatedphase_3

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

NCT02227784
terminatedphase_3

A Study of Evacetrapib in High-Risk Vascular Disease

NCT01687998
completedphase_1

A Study of Different Particle Sizes of Evacetrapib in Healthy Participants

NCT02497391
completedphase_1

A Study of Evacetrapib in Healthy Japanese Participants

NCT02226653
completedphase_1

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

NCT01836185
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT02227784Phase 3

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Terminated
NCT01687998Phase 3

A Study of Evacetrapib in High-Risk Vascular Disease

Terminated
NCT02497391Phase 1

A Study of Different Particle Sizes of Evacetrapib in Healthy Participants

Completed
NCT02226653Phase 1

A Study of Evacetrapib in Healthy Japanese Participants

Completed
NCT01836185Phase 1

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Completed
NCT01810432Phase 1

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Completed
NCT02156492Phase 1

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

Completed
NCT01958489Phase 1

A Study of Evacetrapib in Japanese and Non-Japanese Participants

Completed
NCT01825889Phase 1

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Completed
NCT02260635Phase 3

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Terminated
NCT01897493Phase 1

A Study of Evacetrapib and Digoxin in Healthy Participants

Completed
NCT01746732Phase 1

A Study of Evacetrapib in Healthy Female Participants

Completed
NCT02260648Phase 3

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Terminated
NCT01903434Phase 1

A Study of Evacetrapib (LY2484595) in Healthy Participants

Completed
NCT01825876Phase 1

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Completed
NCT02365558Phase 1

A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

Completed
NCT01908582Phase 1

A Study of Evacetrapib and Rifampin in Healthy Participants

Completed
NCT02168803Phase 1

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Completed
NCT01736254Phase 1

A Study of Evacetrapib in Healthy Participants

Completed
NCT02161731Phase 1

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20